| Original language | English (US) |
|---|---|
| Pages (from-to) | 3501-3505 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 62 |
| Issue number | 14 |
| DOIs | |
| State | Published - 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
MD Anderson CCSG core facilities
- Biostatistics Resource Group
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia and Lymphoma, Vol. 62, No. 14, 2021, p. 3501-3505.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine
AU - Venugopal, Sangeetha
AU - Maiti, Abhishek
AU - DiNardo, Courtney D.
AU - Qiao, Wei
AU - Ning, Jing
AU - Loghavi, Sanam
AU - Daver, Naval G.
AU - Kadia, Tapan M.
AU - Rausch, Caitlin R.
AU - Alvarado, Yesid
AU - Ohanian, Maro
AU - Sasaki, Koji
AU - Short, Nicholas J.
AU - Takahashi, Koichi
AU - Yilmaz, Musa
AU - Ravandi, Farhad
AU - Kantarjian, Hagop M.
AU - Konopleva, Marina
N1 - Funding Information: This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health. We thank the patients, their caregivers, and members of the study team involved in this trial. Clinical trial registration information: https://clinicaltrials.gov/ct2/show/NCT03404193 Institutional review board approval and ethics committee clearance: obtained. Prior presentation : Presented as a poster in the European Haematology Association Annual Conference 2021. Funding Information: SV: none. AM: research funding from Celgene Corporation. CDD: personal fees from Abbvie, personal fees from Agios, personal fees from Novartis, personal fees from ImmuneOnc, personal fees from Daiichi Sankyo, personal fees from Celgene, personal fees from Jazz, personal fees from Notable Labs, outside the submitted work. SL: none. NGD: reports grant from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty-seven; personal fees from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Jazz pharmaceuticals, Trillium, Forty-seven, Gilead, Kite, Novartis. TMK: none. CRR: none. YA: none. MO: none. KS: none. NJS: reports grant from Takeda Oncology, Astellas; Personal fees from Takeda Oncology, AstraZeneca, Amgen. KT: has received personal fees for service on advisory boards of Symbio Pharmaceuticals, GSK, Celgene. MY: none. FR: none. HMK: grants and other from AbbVie, grants and other from Agios, grants and other from Amgen, grants from Ariad, grants from Astex, grants from BMS, from Cyclacel, grants from Daiichi-Sankyo, grants and other from Immunogen, grants from Jazz Pharma, grants from Novartis, grants and other from Pfizer, other from Actinium, other from Takeda, outside the submitted work. MYK: has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty-Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Astra Zeneca; Consulting/honorarium from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85114388082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114388082&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1973675
DO - 10.1080/10428194.2021.1973675
M3 - Letter
C2 - 34474640
AN - SCOPUS:85114388082
SN - 1042-8194
VL - 62
SP - 3501
EP - 3505
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -